Stock comparison
GE HealthCare Technologies
Royalty Pharma
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
GEHC
GE HealthCare Technologies
Market cap
$29.22B
Sector
Healthcare
RPRX
Royalty Pharma
Market cap
$23.44B
Sector
Healthcare
Overall winner
Royalty Pharma RPRX
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | GEHC | RPRX | Winner |
|---|---|---|---|
| Warren Buffett | 46D | 66C | RPRX |
| Benjamin Graham | 63C | 84A | RPRX |
| Philip Fisher | 33F | 65C | RPRX |
| Peter Lynch | 25F | 60C | RPRX |
| Joel Greenblatt | 30F | 40D | RPRX |
| Charlie Munger | 45D | 68D | RPRX |
| Terry Smith | 34F | 58D | RPRX |
Side-by-side metrics
| Metric | GEHC | RPRX |
|---|---|---|
| Market cap | $29.22B | $23.44B |
| P/E (TTM) | 18.4x | 27.6x |
| EV/EBIT | 13.0x | 19.9x |
| ROIC (TTM) | 6.71% | 8.43% |
| Gross margin | 42.55% | 99.95% |
| Net margin | 7.54% | 33.91% |
| Revenue CAGR 5y | 4.07% | 0.96% |
| EPS CAGR 5y | -1.78% | 11.83% |
| Debt / Equity | 1.0x | 1.3x |
| Dividend yield | 0.23% | 1.72% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
GEHC leads on
- Revenue CAGR 5y4.07%vs 0.96%+77%
- EV/EBIT13.0xvs 19.9x+35%
- P/E (TTM)18.4xvs 27.6x+33%
- Debt / Equity1.0xvs 1.3x+24%
RPRX leads on
- EPS CAGR 5y11.83%vs -1.78%+115%
- Dividend yield1.72%vs 0.23%+87%
- Net margin33.91%vs 7.54%+78%
- Gross margin99.95%vs 42.55%+57%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.